Jessica Connor1, Elizabeth A Olear1, Karl L Insogna1, Lee Katz1, Suher Baker1, Raghbir Kaur1, Christine A Simpson1, John Sterpka1, Robert Dubrow1, Jane H Zhang1, Thomas O Carpenter1. 1. Departments of Epidemiology and Public Health (J.C., R.D.), Medicine (K.L.I., C.A.S., J.S.), Pediatrics (E.A.O., T.O.C.), and Diagnostic Imaging (L.K.), Yale University School of Medicine, Yale-New Haven Hospital Dentistry Program (S.B., R.K.), New Haven, Connecticut 06520; and the Veterans Administration Cooperative Studies Program Coordinating Center, Veterans Affairs Connecticut Healthcare System (J.H.Z.), West Haven, Connecticut 06516.
Abstract
CONTEXT: Treatment of X-linked hypophosphatemia (XLH) with active vitamin D metabolites and phosphate can partially correct skeletal deformities. It is unclear whether therapy influences the occurrence of two major long-term morbidities in XLH: enthesopathy and dental disease. OBJECTIVE: The objective of the study was to investigate the relationship between treatment and enthesopathy and dental disease in adult XLH patients. DESIGN: The study was designed as observational and cross-sectional. SETTING: The study was conducted at an academic medical center's hospital research unit. PARTICIPANTS: Fifty-two XLH patients aged 18 years or older at the time of the study participated in the study. INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: The number of enthesopathy sites identified by radiographic skeletal survey and dental disease severity (more than five or five or fewer dental abscesses), identified historically, were measured. METHODS: Associations between proportion of adult life and total life with treatment and number of enthesopathy sites were assessed using multiple linear regression, whereas associations between these exposure variables and dental disease severity were assessed using multiple logistic regression. All models were adjusted for confounding factors. RESULTS: Neither proportion of adult nor total life with treatment was a significant predictor of extent of enthesopathy. In contrast, both of these treatment variables were significant predictors of dental disease severity (multivariate-adjusted global P = .0080 and P = .0010, respectively). Participants treated 0% of adulthood were more likely to have severe dental disease than those treated 100% of adulthood (adjusted odds ratio 25 [95% confidence interval 1.2-520]). As the proportion of adult life with treatment increased, the odds of having severe dental disease decreased (multivariate-adjusted P for trend = .015). CONCLUSIONS: Treatment in adulthood may not promote or prevent enthesopathy; however, it may be associated with a lower risk of experiencing severe dental disease.
CONTEXT: Treatment of X-linked hypophosphatemia (XLH) with active vitamin D metabolites and phosphate can partially correct skeletal deformities. It is unclear whether therapy influences the occurrence of two major long-term morbidities in XLH: enthesopathy and dental disease. OBJECTIVE: The objective of the study was to investigate the relationship between treatment and enthesopathy and dental disease in adult XLH patients. DESIGN: The study was designed as observational and cross-sectional. SETTING: The study was conducted at an academic medical center's hospital research unit. PARTICIPANTS: Fifty-two XLH patients aged 18 years or older at the time of the study participated in the study. INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: The number of enthesopathy sites identified by radiographic skeletal survey and dental disease severity (more than five or five or fewer dental abscesses), identified historically, were measured. METHODS: Associations between proportion of adult life and total life with treatment and number of enthesopathy sites were assessed using multiple linear regression, whereas associations between these exposure variables and dental disease severity were assessed using multiple logistic regression. All models were adjusted for confounding factors. RESULTS: Neither proportion of adult nor total life with treatment was a significant predictor of extent of enthesopathy. In contrast, both of these treatment variables were significant predictors of dental disease severity (multivariate-adjusted global P = .0080 and P = .0010, respectively). Participants treated 0% of adulthood were more likely to have severe dental disease than those treated 100% of adulthood (adjusted odds ratio 25 [95% confidence interval 1.2-520]). As the proportion of adult life with treatment increased, the odds of having severe dental disease decreased (multivariate-adjusted P for trend = .015). CONCLUSIONS: Treatment in adulthood may not promote or prevent enthesopathy; however, it may be associated with a lower risk of experiencing severe dental disease.
Authors: Erik A Imel; Francis H Glorieux; Michael P Whyte; Craig F Munns; Leanne M Ward; Ola Nilsson; Jill H Simmons; Raja Padidela; Noriyuki Namba; Hae Il Cheong; Pisit Pitukcheewanont; Etienne Sochett; Wolfgang Högler; Koji Muroya; Hiroyuki Tanaka; Gary S Gottesman; Andrew Biggin; Farzana Perwad; Meng Mao; Chao-Yin Chen; Alison Skrinar; Javier San Martin; Anthony A Portale Journal: Lancet Date: 2019-05-16 Impact factor: 79.321
Authors: Rebecca Sullivan; Alice Abraham; Christine Simpson; Elizabeth Olear; Thomas Carpenter; Yanhong Deng; Chuqing Chen; Karl L Insogna Journal: Calcif Tissue Int Date: 2018-01-30 Impact factor: 4.333
Authors: Anupam Kotwal; Alejandro Ferrer; Rajiv Kumar; Ravinder J Singh; Vishakantha Murthy; Laura Schultz-Rogers; Michael Zimmermann; Brendan Lanpher; Kristin Zimmerman; Paul R Stabach; Eric Klee; Demetrios T Braddock; Robert A Wermers Journal: J Bone Miner Res Date: 2020-01-16 Impact factor: 6.741